| Ytd | -52.13% | |
| 1y | 66.94% |
| Open | 3.95 | Prev Close | 4.00 | Low | 3.53 | High | 4.05 | Mkt Cap | 75.56M |
| Vol | 395.38K | Avg Vol | 266.40K | EPS | -2.15 | P/E | -1.88 | Forward P/E | N/A |
| Beta | 0.19 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 4.61 | 200-d Avg | 6.65 | 1yr Est | 0.00 |
KLRS News
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical co
Strategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolst
Kalaris Therapeutics (NASDAQ: KLRS) stock jumps 18% after releasing expanded Phase 1a data for its A
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreat
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreat
Wedbush analyst Yun Zhong initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Outperf
Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Out
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.46) per share which beat the ana
Top analysts change outlook on top names, check analyst ratings page for all changes. Keybanc initia
Morgan Stanley analyst Judah Frommer initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) wit
Up to $100,000,000Kalaris Therapeutics, Inc.Common StockWe have entered into a sales agreement with
https://www.sec.gov/ix?doc=/Archives/edgar/data/1754068/000119312526151215/d108368d8k.htm
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.44) per share which beat the ana
